Sihuan Pharm (00460) rose more than 5%. As of the time of publication, it has risen by 5.36% to HKD 0.59, with a turnover of HKD 9.8978 million.
According to the Zhongtong Caijing APP, Sihuan Pharm (00460) rose more than 5%. As of the time of publication, it has risen by 5.36% to HKD 0.59, with a turnover of HKD 9.8978 million.
Recently, Sihuan Pharm announced that the clinical trial application (IND application) for its Somatostatin Analog Injection developed by its non-wholly-owned subsidiary, Huisheng Biotech, for use in overweight or obese patients (collectively referred to as "weight loss"), has been accepted by the China National Medical Products Administration. The global sales of Somatostatin Analog Injection surpassed USD 20 billion in 2023, of which the sales for weight loss were approximately USD 4.5 billion, an increase of over 400% compared to 2022, showing explosive growth.